Tasisulam(LY573636)|cas 519055-62-0| DC Chem|Supplier|Price|Buy  

Tasisulam(LY573636)|cas 519055-62-0| DC Chem|Supplier|Price|Buy

DC Chemicals Supply: Tasisulam(LY573636)|cas 519055-62-0,Purity: >98% ,Cat No. DC7312, In stock.

Contact: website: www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642781；

Tasisulam(LY573636)|cas 519055-62-0 ,Synonym: LY573636-sodium;  benzamide ,Chemical name: Benzamide,N-[(5-bromo-2-thienyl)sulfonyl]-2,4-dichloro- ,Molecular Formula: C11H6BrCl2NO3S2 ,MW:415.11

Tasisulam(LY573636), cas 519055-62-0,Purity: >98%, Best Price and quality from DC Chemicals. Tasisulam sodium is The sodium salt of an acyl-sulfonamide with potential antineoplastic activity. Selectively toxic towards tumor cells, tasisulam appears to induce tumor cell apoptosis by a mitochondrial-targeted mechanism involving the loss of mitochondrial membrane potential and induction of reactive oxygen species (ROS). In combination with an angiogenesis inhibitor, this agent may exhibit synergistic antiangiogenic activity.

Tasisulam inhibits growth of various human leukemia and lymphoma cell lines with ED50 ranging from 7 to 40 μM. LY573636 also induces apoptosis in HL60, Reh, and MD901 cells, mainly by loss of mitochondrial membrane potential and induction of reactive oxygen species. [1] In addition, Tasisulam also produce antiproliferative activities in more than 70% of the 120 cell lines tested with EC50 of less than 50 μM. Tasisulam induces G2–M accumulation and subsequent apoptosis in Calu-6 and A-375 cells. In vitro, Tasisulam also inhibits VEGF-, FGF- and EGF-induced endothelial cord formation with EC50 of 47, 103, and 34 nM, respectively. [2] Tasisulam induces morphologic features of vascular normalization, including increased pericyte coverage and decreased hypoxia in vivo. Tasisulam (25 or 50 mg/kg, i.v.) displays dose-dependent antitumor activity, induces apoptosis, and normalizes tumor-associated vasculature in the Calu-6 non–small cell lung xenograft model. Besides, Tasisulam displays potent antitumor activity across a range of in vivo xenografts, including colorectal (HCT-116), melanoma (A-375), gastric (NUGC-3), leukemia (MV-4-11), and pancreatic (QGP-1). [2]